Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Dyno Therapeutics, Inc.

News headline image
Dyno Therapeutics Launches Dyno Psi-Phi, an Agentic AI Suite for Protein Binder Design, at NVIDIA GTC 2026
From Dyno Therapeutics, Inc.
Via Business Wire
News headline image
Dyno Therapeutics Launches Dyno-yp2, a Top-Performing TfR1-Mediated AAV Capsid, to Further Diversify CNS Delivery Portfolio
From Dyno Therapeutics, Inc.
Via Business Wire
News headline image
Dyno Therapeutics Unveils Best-in-Class Dyno-bn8 AAV Vector for Muscle Gene Therapies, Achieving Therapeutic Delivery With Improved Safety Potential
From Dyno Therapeutics, Inc.
Via Business Wire
News headline image
Dyno Therapeutics and Trisk Bio Announce Strategic Manufacturing Partnership Through Expanded Frontiers Program
From Dyno Therapeutics, Inc.
Via Business Wire
News headline image
Dyno Therapeutics Launches Three Breakthrough Capsid Delivery Vectors for Next-Generation Eye, Muscle and CNS Gene Therapies at the 2025 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
From Dyno Therapeutics, Inc.
Via Business Wire
News headline image
Dyno Therapeutics Announces Inaugural 2025 Genetic Agency Technology Conference and Launch of Dyno Frontiers Program to Accelerate Progress in Patient-Empowering Gene Therapies
From Dyno Therapeutics, Inc.
Via Business Wire
News headline image
Dyno Therapeutics to Present Breakthrough Data on AAV Gene Delivery to the CNS, Eye, and Muscle at the 28th Annual Meeting of the American Society of Gene & Cell Therapy
From Dyno Therapeutics, Inc.
Via Business Wire
News headline image
Dyno Therapeutics Announces Exercise of Option by Roche for Next-Generation AAV Vector for Neurological Gene Therapy
From Dyno Therapeutics, Inc.
Via Business Wire
News headline image
Dyno Therapeutics Unveils Path to Exponentially Reducing the Cost of In Vivo Gene Delivery at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
From Dyno Therapeutics, Inc.
Via Business Wire
News headline image
Dyno Therapeutics to Present on Breakthroughs in AI Methods for AAV Capsid Design at ASGCT Annual Congress and SynBioBeta Global Synthetic Biology Conference
From Dyno Therapeutics, Inc.
Via Business Wire
News headline image
Dyno Therapeutics Launches Dyno eCap 1™ Vector, a Field-Leading AAV Capsid for Eye Gene Therapies
From Dyno Therapeutics, Inc.
Via Business Wire
News headline image
Dyno Therapeutics to Present on Breakthrough Optimized AAV Capsids for Eye and CNS Gene Delivery at ESGCT Annual Congress
From Dyno Therapeutics, Inc.
Via Business Wire
News headline image
Dyno Therapeutics Launches the Dyno bCap 1™ Capsid Product, a Breakthrough CNS Gene Delivery Vector Created with Generative Artificial Intelligence
From Dyno Therapeutics, Inc.
Via Business Wire
News headline image
Dyno Therapeutics to Present New Data on Optimized AAV Capsids with Transformative Therapeutic Delivery Potential at 2023 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
From Dyno Therapeutics, Inc.
Via Business Wire
News headline image
Dyno Therapeutics Presents State-of-the-Art Applications of Machine Learning to Design Improved AAV Capsids for a Broad Range of Gene Therapies at American Society of Gene and Cell Therapy Conference
From Dyno Therapeutics, Inc.
Via Business Wire
News headline image
Dyno Therapeutics Closes $100 Million Series A Financing Led by Andreessen Horowitz to Accelerate AI‑powered Gene Therapy Platform
From Dyno Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.